MT1-MMP catalytic activity decreases the expression of the tumor suppressor SPRY4 in metastatic melanoma through an MMP-2/RAC1 pathway; a higher expression of SPRY4 correlated with a longer survival of melanoma patients [137]. Here, MMP14 is linked to melanoma.